Summary of the SARS-CoV-2 related CPT codes that have been approved and published for the 2021 CPT code set.
- Accepted addition of code 87635 to report infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique. The new code was effective March 13, 2020.
- Accepted revision of code 86318 to report immunoassay for infectious agent antibody(ies) and to be a parent to 86328; addition of code 86328 to report single step antibody testing for severe acute respiratory syndrome coronavirus 2; addition of child code 86769 to report multiple-step antibody testing for severe acute respiratory syndrome coronavirus 2; and revision of the Immunology guidelines. The new codes and revision were effective April 10, 2020.
- Accepted addition of PLA code 0202U to report the BioFire® Respiratory Panel 2.1 (RP2.1) test. The new code was effective May 20, 2020.
- Accepted addition of code 87426 to report infectious agent antigen detection by immunoassay technique of SARS-CoV and SARS-CoV-2. In addition, two new PLA codes (0223U and 0224U) were accepted for detection of SARS-CoV-2.
- Accepted addition of codes 86408 for reporting coronavirus 2 (SARS-CoV-2) neutralizing antibody screen and 86409 for reporting coronavirus 2 (SARS-CoV-2) neutralizing antibody titer. In addition, two new PLA codes (0225U and 0226U) were accepted for detection of SARS-CoV-2. These new codes are effective Aug. 10, 2020.
- Accepted addition of code 99072 for the additional supplies and clinical staff time required to mitigate transmission of respiratory infectious disease while providing evaluation, treatment, or procedural services during a public health emergency, as defined by law. In addition, one code, 86413, was created for reporting quantitative antibody detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Accepted addition of code 87636 for reporting combined respiratory virus multiplex testing for either SARS-CoV-2 with Influenza A&B, code 87637 for combined respiratory virus multiplex testing for either SARS-CoV-2 with Influenza A&B and RSV and 87811for antigen detection of SARS-CoV-2 by direct optical (i.e., visual) observation. Two new PLA codes (0240U and 0241U) were accepted for detection of SARS-CoV-2, Influenza A and Influenza B; code 0241U also detects RSV. Additionally, Immunology guidelines were also revised, along with codes 87301, 87802 and their subsidiary codes.
- Accepted addition of code 87428 for reporting multiplex viral pathogen panel using antigen immunoassay technique for SARS-CoV-2 testing along with influenza A and influenza B.
- Accepted addition of codes 91300, 91301 to report Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccines and codes 0001A, 0002A, 0011A, 0012A to report the immunization administration of these vaccines.
References:
https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance
